Thermo Fisher Scientific’s Invitrogen Vivofectamine™ Delivery Solutions mark a breakthrough in non-viral delivery of nucleic acids. This cutting-edge lipid nanoparticle (LNP) portfolio, featuring over 6,000 chemically diverse ionizable lipids, provides researchers and developers with tools for efficient and safe in vivo delivery.

Transforming genetic medicine

The adoption of non-viral delivery technologies like Vivofectamine is driven by the success of mRNA vaccines and the demand for safer alternatives to viral vectors. This LNP technology supports applications ranging from gene editing and replacement therapies to cancer and prophylactic vaccines.

Key features of vivofectamine delivery solutions

• Versatile Options: Custom and catalog reagents tailored for research and drug development.
• Safety Standards: Proven tolerability in animal studies with flexible dosing.
• Optimized Efficiency: Delivery to diverse tissue types, including liver, immune cells, and tumors.
• Innovation-Driven: Enhances in vivo applications such as intramuscular and systemic delivery.

With Invitrogen Vivofectamine, researchers can explore groundbreaking applications while reducing time and costs associated with nucleic acid delivery.